Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1984;18 Suppl 2(Suppl 2):249S-253S, 255S.
doi: 10.1111/j.1365-2125.1984.tb02604.x.

Tolerance and safety of enalapril

W McFate Smith, R O Davies, M A Gabriel, D M Kramsch, F Moncloa, J E Rush, J F Walker
Clinical Trial

Tolerance and safety of enalapril

W McFate Smith et al. Br J Clin Pharmacol. 1984.

Abstract

Enalapril is the result of a targeted research programme to develop a non-mercapto converting enzyme inhibitor with a long duration of action and an improved safety profile for use in the therapy of hypertension and congestive heart failure. Over 3500 patients world-wide have received enalapril or enalaprilat. Long-term experience at present includes over 2500 patients. While enalapril and captopril produce similar efficacy, enalapril is better tolerated and appears not to be associated with occurrence of captopril-type side-effects, particularly the skin rash, taste loss, leukopenia and proteinuria. Enalapril and other converting enzyme inhibitors may be associated with renal insufficiency when given to patients with bilateral renovascular hypertension.

PubMed Disclaimer

References

    1. Clin Pharmacol Ther. 1982 Jul;32(1):48-53 - PubMed
    1. Arch Intern Med. 1984 Jul;144(7):1441-4 - PubMed
    1. J Cardiovasc Pharmacol. 1982 Nov-Dec;4(6):966-72 - PubMed
    1. Lancet. 1982 Aug 21;2(8295):440 - PubMed

Publication types